<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02159547</url>
  </required_header>
  <id_info>
    <org_study_id>41/10</org_study_id>
    <nct_id>NCT02159547</nct_id>
  </id_info>
  <brief_title>IV Dexketoprofen vs Placebo in Migranie Attack</brief_title>
  <official_title>Study of Comparing Dexketoprofen to Placebo in Migraine Attack</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Akdeniz University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Akdeniz University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      H0 hypothesis: IV dexketoprofen is equivalent to placebo in ceasing migraine attack in
      emergency department.

      H1 hypothesis: IV dexketoprofen is not equivalent (superior) to placebo in ceasing migraine
      attack in emergency department.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Migraine attack is one of the most leading causes presentations to emergency department.
      Patients with migraine attack seek urgent care to cease their pain. There are so many
      interventions defined in the medical literature that can be used in migraine attacks.
      However, as a IV drug, dexketoprofen; little known whether IV dexketoprofen is superior to
      placebo or not. In the present study we aimed to determine the effects of IV dexketoprofen in
      migraine attack in emergency department.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual Analogue Scale Change</measure>
    <time_frame>45 minutes</time_frame>
    <description>Change from baseline in Visual Analogue Scale, 100 mm, at 45th minutes. Visual Analogue Scale is measurement tool scoring tool between 0 (no pain) and 100 mm (worst pain). Minimum clinically significant change in pain score is 13 or 16 mm.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Effects</measure>
    <time_frame>45th minutes</time_frame>
    <description>The adverse effects is being recorded to the study form after the study drugs are administered at the 45th minutes.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">224</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Dexketoprofen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>50 mg intravenous dexketoprofen in 50 ml normal saline in 5 minutes infusion.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>normal slaline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>50 ml normal saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexketoprofen</intervention_name>
    <description>50 mg intravenous arveles in 50 ml saline in 5 minutes</description>
    <arm_group_label>Dexketoprofen</arm_group_label>
    <other_name>Arveles</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Normal Saline</intervention_name>
    <description>50 ml normal saline</description>
    <arm_group_label>normal slaline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients presented with headache who diagnosed as migraine attack according to the
             international headache society

        Exclusion Criteria:

          -  denied to give inform concent, illiterate patients, chronic renal failure, taking
             NSAIDs during the last six hours, pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Faruk Gungor, Pyhsician</last_name>
    <role>Principal Investigator</role>
    <affiliation>Antalya Training and Govermental Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Antalya Training and Govermental Hospital</name>
      <address>
        <city>Antalya</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Turkcuer I, Serinken M, Eken C, Yilmaz A, Akdag Ã–, Uyan E, Kiray C, Elicabuk H. Intravenous paracetamol versus dexketoprofen in acute migraine attack in the emergency department: a randomised clinical trial. Emerg Med J. 2014 Mar;31(3):182-5. doi: 10.1136/emermed-2013-203044. Epub 2014 Jan 6.</citation>
    <PMID>24394884</PMID>
  </reference>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2014</study_first_submitted>
  <study_first_submitted_qc>June 9, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2014</study_first_posted>
  <results_first_submitted>March 16, 2015</results_first_submitted>
  <results_first_submitted_qc>June 27, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 23, 2015</results_first_posted>
  <last_update_submitted>June 27, 2015</last_update_submitted>
  <last_update_submitted_qc>June 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 23, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Akdeniz University</investigator_affiliation>
    <investigator_full_name>Cenker Eken</investigator_full_name>
    <investigator_title>Associated Proffesor</investigator_title>
  </responsible_party>
  <keyword>migraine, emergency department, dexketoprofen, placebo</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Dexketoprofen</title>
          <description>50 mg intravenous dexketoprofen in 50 ml normal saline in 5 minutes infusion.
Dexketoprofen: 50 mg intravenous arveles in 50 ml saline in 5 minutes</description>
        </group>
        <group group_id="P2">
          <title>Normal Slaline</title>
          <description>50 ml normal saline
Normal Saline: 50 ml normal saline</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="112"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="112"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Dexketoprofen</title>
          <description>50 mg intravenous dexketoprofen in 50 ml normal saline in 5 minutes infusion.
Dexketoprofen: 50 mg intravenous arveles in 50 ml saline in 5 minutes</description>
        </group>
        <group group_id="B2">
          <title>Normal Slaline</title>
          <description>50 ml normal saline
Normal Saline: 50 ml normal saline</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="112"/>
            <count group_id="B2" value="112"/>
            <count group_id="B3" value="224"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.3" spread="11.1"/>
                    <measurement group_id="B2" value="37.6" spread="10.7"/>
                    <measurement group_id="B3" value="36.9" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="83"/>
                    <measurement group_id="B3" value="168"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Turkey</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="112"/>
                    <measurement group_id="B2" value="112"/>
                    <measurement group_id="B3" value="224"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Visual Analogue Scale Change</title>
        <description>Change from baseline in Visual Analogue Scale, 100 mm, at 45th minutes. Visual Analogue Scale is measurement tool scoring tool between 0 (no pain) and 100 mm (worst pain). Minimum clinically significant change in pain score is 13 or 16 mm.</description>
        <time_frame>45 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexketoprofen</title>
            <description>50 mg intravenous dexketoprofen in 50 ml normal saline in 5 minutes infusion.</description>
          </group>
          <group group_id="O2">
            <title>Normal Slaline</title>
            <description>50 ml normal saline
Normal Saline: 50 ml normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Visual Analogue Scale Change</title>
          <description>Change from baseline in Visual Analogue Scale, 100 mm, at 45th minutes. Visual Analogue Scale is measurement tool scoring tool between 0 (no pain) and 100 mm (worst pain). Minimum clinically significant change in pain score is 13 or 16 mm.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="49" upper_limit="60"/>
                    <measurement group_id="O2" value="30" lower_limit="25" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adverse Effects</title>
        <description>The adverse effects is being recorded to the study form after the study drugs are administered at the 45th minutes.</description>
        <time_frame>45th minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Dexketoprofen</title>
            <description>50 mg intravenous dexketoprofen in 50 ml normal saline in 5 minutes infusion.
Dexketoprofen: 50 mg intravenous arveles in 50 ml saline in 5 minutes</description>
          </group>
          <group group_id="O2">
            <title>Normal Slaline</title>
            <description>50 ml normal saline
Normal Saline: 50 ml normal saline</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Effects</title>
          <description>The adverse effects is being recorded to the study form after the study drugs are administered at the 45th minutes.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="112"/>
                <count group_id="O2" value="112"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Dexketoprofen</title>
          <description>50 mg intravenous dexketoprofen in 50 ml normal saline in 5 minutes infusion.
Dexketoprofen: 50 mg intravenous arveles in 50 ml saline in 5 minutes</description>
        </group>
        <group group_id="E2">
          <title>Normal Slaline</title>
          <description>50 ml normal saline
Normal Saline: 50 ml normal saline</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="112"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="112"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Cenker EKEN</name_or_title>
      <organization>Akdeniz University</organization>
      <phone>00905321593948</phone>
      <email>cenkereken@akdeniz.edu.tr</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

